Notably, a genetically engineered prolactin-humanized mouse expressing physiological levels of human prolactin demonstrated a greatly improved take rate for ER-positive luminal breast cancers, which were found to be more responsive to tamoxifen [80]. This evidence concerns the gene PRL and breast carcinoma.